Equities research analysts forecast that Eli Lilly and Co (NYSE:LLY) will post $5.52 billion in sales for the current fiscal quarter, according to Zacks Investment Research. Four analysts have made estimates for Eli Lilly and’s earnings, with estimates ranging from $5.45 billion to $5.63 billion. Eli Lilly and reported sales of $5.23 billion during the same quarter last year, which indicates a positive year-over-year growth rate of 5.5%. The business is scheduled to issue its next earnings results before the market opens on Tuesday, April 24th.
According to Zacks, analysts expect that Eli Lilly and will report full year sales of $23.43 billion for the current year, with estimates ranging from $23.15 billion to $23.67 billion. For the next year, analysts forecast that the company will post sales of $23.83 billion per share, with estimates ranging from $23.31 billion to $24.17 billion. Zacks’ sales calculations are a mean average based on a survey of sell-side analysts that cover Eli Lilly and.
Eli Lilly and (NYSE:LLY) last announced its quarterly earnings results on Wednesday, January 31st. The company reported $1.14 EPS for the quarter, topping analysts’ consensus estimates of $1.08 by $0.06. Eli Lilly and had a positive return on equity of 33.01% and a negative net margin of 0.89%. The company had revenue of $6.16 billion during the quarter, compared to analyst estimates of $5.93 billion. During the same quarter last year, the firm posted $0.95 earnings per share. The firm’s revenue was up 7.0% on a year-over-year basis.
A number of analysts recently commented on LLY shares. Argus raised Eli Lilly and from a “hold” rating to a “buy” rating and raised their price target for the stock from $85.52 to $115.00 in a research note on Friday, January 5th. Goldman Sachs lowered Eli Lilly and from a “buy” rating to a “neutral” rating and raised their price target for the stock from $86.98 to $95.00 in a research note on Tuesday, January 16th. Jefferies Group set a $100.00 price target on Eli Lilly and and gave the stock a “buy” rating in a research note on Tuesday, January 16th. Credit Suisse Group lowered Eli Lilly and from a “neutral” rating to an “underperform” rating and set a $82.00 price target for the company. in a research note on Monday, January 22nd. Finally, BMO Capital Markets raised their price target on Eli Lilly and from $73.00 to $74.00 and gave the stock an “underperform” rating in a research note on Thursday, February 1st. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and twelve have issued a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $93.16.
LLY stock traded down $0.69 on Monday, reaching $79.03. The company’s stock had a trading volume of 3,009,605 shares, compared to its average volume of 4,651,781. Eli Lilly and has a 12-month low of $73.69 and a 12-month high of $89.09. The firm has a market capitalization of $87,560.18, a price-to-earnings ratio of 18.43, a PEG ratio of 1.46 and a beta of 0.26. The company has a quick ratio of 1.01, a current ratio of 1.32 and a debt-to-equity ratio of 0.85.
In other news, insider Donald A. Zakrowski sold 860 shares of the firm’s stock in a transaction on Thursday, March 1st. The stock was sold at an average price of $76.50, for a total transaction of $65,790.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Joshua L. Smiley sold 3,000 shares of the firm’s stock in a transaction on Friday, March 16th. The shares were sold at an average price of $79.20, for a total value of $237,600.00. Following the transaction, the chief financial officer now owns 20,029 shares of the company’s stock, valued at $1,586,296.80. The disclosure for this sale can be found here. Insiders have sold 42,970 shares of company stock valued at $3,444,557 in the last three months. Insiders own 0.11% of the company’s stock.
Large investors have recently modified their holdings of the company. Sei Investments Co. lifted its stake in Eli Lilly and by 9.5% in the third quarter. Sei Investments Co. now owns 1,292,772 shares of the company’s stock valued at $110,585,000 after acquiring an additional 112,532 shares during the last quarter. Ballentine Partners LLC lifted its stake in Eli Lilly and by 67.6% in the third quarter. Ballentine Partners LLC now owns 4,970 shares of the company’s stock valued at $426,000 after acquiring an additional 2,004 shares during the last quarter. Meag Munich Ergo Kapitalanlagegesellschaft MBH acquired a new stake in Eli Lilly and in the third quarter valued at $11,731,000. Retirement Systems of Alabama lifted its stake in shares of Eli Lilly and by 7.3% during the 3rd quarter. Retirement Systems of Alabama now owns 751,855 shares of the company’s stock worth $64,314,000 after buying an additional 51,466 shares during the last quarter. Finally, CIBC Asset Management Inc lifted its stake in shares of Eli Lilly and by 1.8% during the 3rd quarter. CIBC Asset Management Inc now owns 105,720 shares of the company’s stock worth $9,043,000 after buying an additional 1,868 shares during the last quarter. Hedge funds and other institutional investors own 77.66% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “$5.52 Billion in Sales Expected for Eli Lilly and Co (LLY) This Quarter” was originally published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright law. The original version of this news story can be read at https://ledgergazette.com/2018/04/19/5-52-billion-in-sales-expected-for-eli-lilly-and-co-lly-this-quarter.html.
Eli Lilly and Company Profile
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.